| Nov 12 |
Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib
|
| Nov 8 |
Analysts Are Updating Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Estimates After Its Third-Quarter Results
|
| Nov 7 |
Q3 2024 Royalty Pharma PLC Earnings Call
|
| Nov 6 |
Q3 2024 Syndax Pharmaceuticals Inc Earnings Call
|
| Nov 6 |
Moderna said to shuffle sales leadership; Vertex records first Casgevy sale
|
| Nov 6 |
Syndax Pharmaceuticals Inc (SNDX) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
|
| Nov 6 |
Syndax Pharmaceuticals, Inc. (SNDX) Q3 2024 Earnings Call Transcript
|
| Nov 5 |
Syndax Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call Presentation
|
| Nov 5 |
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Tops Revenue Estimates
|
| Nov 5 |
Syndax Pharmaceuticals GAAP EPS of -$0.98 beats by $0.05, revenue of $12.5M beats by $4.1M
|
